期刊文献+

强直性脊柱炎骨质破坏的发病机制研究进展 被引量:4

下载PDF
导出
摘要 强直性脊柱炎是一种病因复杂、起病隐匿的血清阴性脊柱关节病,发病机制不清。但其病理学特点为早期韧带、纤维环、椎间盘、骨膜和骨小梁为血管化和纤维性组织侵犯,被肉芽组织取代,导致整个关节破坏和附近骨质硬化,最终关节纤维性及骨性强直。这些特点与脊柱周围韧带、滑膜内细胞及其分泌的细胞因子有关,现就近年来有关参与强直性脊柱炎骨质破坏的细胞及细胞因子作一综述。
出处 《颈腰痛杂志》 2008年第2期156-159,共4页 The Journal of Cervicodynia and Lumbodynia
  • 相关文献

参考文献23

  • 1Suzuki Y,Tsutsumi Y,Nakagawa M,et al. Osteoclast-like cells in an in vitro model of bone destruction by rheumatoid synovium[J]. Rheumatology( Oxford ) ,2001,40: 673-682.
  • 2Redlich K,Hayer S,Ricci R,et al. Osteoclasts are essential for TNF-a mediated joint destruction [J]. J Clin Invest,2002,110 (10) : 1419-1427.
  • 3Vandooren B,Kruithof E,Yu DT,et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy [J]. Arthritis Rheum, 2004.50: 2942-2953.
  • 4Lijnen H.R. Elements of the fibrinolytie system[J]. Ann N Y Acad Sci,2001,936:226- 236.
  • 5Maksymowych WP,Jhangri GS,Lambert RG, et al. Infliximab in ankylosing spondylitis:a prospective observational inception cohort analysis of efficacy and safety[J]. J Rheumatol, 2002,29 : 959-965.
  • 6Brandt J,Hailbel H,Sieper J,et al. Infliximab treatment of severe ankylosing spondylitis:one-year follow-up [J]. Arthritis Rheum, 2002,44(12):2936-2945.
  • 7赵伟,黄烽.细胞核因子κB受体活化因子配基在强直性脊柱炎的表达及意义[J].解放军医学杂志,2004,29(6):482-485. 被引量:26
  • 8Moil H,Kitazawa R,Mizuki S,et al. ASNKligand,ASNK,and OPGex2 pression in type Ⅱ collagen-induced arthritis mouse [J]. Histochem Cell Biol, 2002, 117:283-292.
  • 9赵伟,黄烽.护骨素在强直性脊柱炎外周关节骨质破坏病理机制中的作用[J].中华风湿病学杂志,2005,9(6):329-333. 被引量:17
  • 10[0]Pettit AR,Ji H,von Stechow D,et al. TASNCE/ASNKL knockout mice are protected from bone erosion in a serum tASnsfer model of arthritis [J]. Am J Pathol, 2001,159:1689-1699.

二级参考文献87

  • 1褚洪涛,张百安.云克与松梅乐治疗强直性脊柱炎疗效对比观察[J].中国误诊学杂志,2004,4(3):418-419. 被引量:19
  • 2Huang F, Gu J, Zhao W, et al. One-year open-hbel trial of thalidomide in ankylosing spondylitis. Arthritis Rheum (Arthritis Care Res), 2002,47: 249-254.
  • 3Davis J, Huang F, Maksymowych WP. New therapies for ankylosing spondylitis: etanercept, thalidomide and pamidronate. Rheum Dis Clin North Am, 2003,29 : 501-517.
  • 4Huang F, Wei J, Breban M. Thalidomide in ankylosing spondylitis.Clin Exp Rheumatol, 2002,20: S158-161.
  • 5Huang F, Gu J, Zhao W, et al. Therapeutic effect and molecular targets of thalidomide in refractory ankylosing spondylitis. Arthritis Rheum,2001,44 : S275.
  • 6Gorman J, Sack K, Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med, 2002,346:1349-1356.
  • 7Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet, 2002,359:1187.
  • 8Antoni C,Bmun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol, 2002,20: S152-157.
  • 9Miyazaki S,Matsukawa A,Ohkawara S,et al. Neutrophil infiltration as a crucial step for monocyte chemoattractant protein (MCP)-1 to attract monocytes in lipopolysaccharied-induced arthritis in rabbits. Inflamm Res,2000,49:673-678.
  • 10Volin M,Harlow L,Woods J,et al. Treatment with sulfasalazine or sulfapyridine,but not 5-aminosalicyclic acid,inhibits basic fibroblast growth factor-inducod endothelial cell chemotaxis. Arthritis Rheum,1999,42:1927-1935.

共引文献94

同被引文献38

  • 1雷飞飞,杨惠琴.强直性脊柱炎骨质疏松发病机制研究[J].湖北中医学院学报,2009,11(1):48-50. 被引量:4
  • 2张宏宇.祝谌予教授四藤一仙汤治验4则[J].新中医,2004,36(8):8-9. 被引量:15
  • 3Miyamolo M,Prause O,Sjostran M,et al.Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse ainvays[J].J lmmunol,2003,170(9):4665-4672.
  • 4Sergejeva S,lvanov S,Lotvall J,et al.Interleukin-17 as a recruitmerit and survival fact or for air waymacrophagesin allergic air way inflammati on[J].Am J Res Pit Cell Mol Biol,2005,33(3):248-253.
  • 5Hartkamp A,Geenen R,Bijl M,et al.Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjgren's syndrome[J].Ann Rheum,2004,63(10):1335-1337.
  • 6Yamaki K,Uchida H,Li X,et al.Elect of varying types of anti-arthritic drugs on Th1 and Th2 immune res ponses in mice[J].Int J Immunopathol Phar maeol,2005,18(6):133-144.
  • 7Rifas L,Arackal S.T cells regulate the expression of matrix metallopmteinase in human osteoblnsts via a dual mitogenactivated protein kinase mechanism[J].Arthritis Rheum.2003.48(4):993-1001.
  • 8Rudwaleit M, van der Heijde D, Landewe R, et al. The developmentof assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis(part Ⅱ): validation and final selection[J]. Ann Rheum Dis, 2009,68(6): 777-783.
  • 9Heijde D, Lie E, Kvien TK. ASDAS, a highly discriminatoryASAS-endorsed disease activity score in patients with ankylosing spondylitis[J]. Ann Rheum Dis, 2009,68: 1811-1818.
  • 10Machado P, Landew6 R, Lie E, et al. Ankylosing SpondylitisDisease Activity Score(ASDAS) : defining cut-off values for disease activity states and improvement scores[J]. Ann Rheum Dis, 2011,70: 47-53.

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部